𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The Effect of Three or Six Years of Denosumab Exposure in Women With Postmenopausal Osteoporosis: Results From the FREEDOM Extension

✍ Scribed by Bone, Henry G.; Chapurlat, Roland; Brandi, Maria-Luisa; Brown, Jacques P.; Czerwiński, Edward; Krieg, Marc-Antoine; Mellström, Dan; Radominski, Sebastião C.; Reginster, Jean-Yves; Resch, Heinrich; Ivorra, Jose A. Román; Roux, Christian; Vittinghoff, Eric; Daizadeh, Nadia S.; Wang, Andrea; Bradley, Michelle N.; Franchimont, Nathalie; Geller, Michelle L.; Wagman, Rachel B.; Cummings, Steven R.; Papapoulos, Socrates

Book ID
121851931
Publisher
Endocrine Society
Year
2013
Tongue
English
Weight
312 KB
Volume
98
Category
Article
ISSN
0021-972X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Five years of denosumab exposure in wome
Five years of denosumab exposure in women with postmenopausal osteoporosis: Results from the first two years of the FREEDOM extension
✍ Socrates Papapoulos; Roland Chapurlat; Cesar Libanati; Maria Luisa Brandi; Jacqu 📂 Article 📅 2012 🏛 American Society for Bone and Mineral Research 🌐 English ⚖ 256 KB 👁 1 views

The 3-year FREEDOM trial assessed the efficacy and safety of 60 mg denosumab every 6 months for the treatment of postmenopausal women with osteoporosis. Participants who completed the FREEDOM trial were eligible to enter an extension to continue the evaluation of denosumab efficacy and safety for up